- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Romney on Drug Prices; Kentucky Delays Work Requirements; Teva's Epinephrine Shortage
Senator Mitt Romney, R-Utah, warned PhRMA that he and his new colleagues are working to tackle the issue of high prescription drug prices; Kentucky is delaying the start of work requirement rules for a portion of its Medicaid population; despite its approval by the FDA last year, Teva’s generic version of an epinephrine autoinjector is not available at the largest pharmacies or through drug distributors.
Romney Tells PhRMA Changes in Drug Pricing Are Coming
Kentucky Delaying Start of Medicaid Work Rules
Teva's Epinephrine in Short Supply Months After Approval
Senator Mitt Romney, R-Utah, warned the Pharmaceutical Research and Manufacturers of America (PhRMA) that he and his new colleagues are working to tackle the issue of high prescription drug prices in a closed-door meeting, STAT News reported. The industry should be prepared to take part in participate in those discussions, he said.Kentucky is delaying the start of work requirement rules for a portion of its Medicaid population, the Associated Press reported. A federal judge blocked the rules last year, but the Trump administration approved them a second time in November. Some of the rules were to start April 1, but they will now begin no sooner than July 1, the state said.Despite its approval by the FDA last year, Teva’s generic version of an epinephrine autoinjector is not available at the largest pharmacies or through drug distributors, Reuters reported. The short supply means Teva cannot compete with Mylan in a roughly $750 million a year US market. Mylan’s EpiPen has also been in short supply since spring 2018. Teva did not say why its drug was in short supply.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
